Clinical trials: Overall Response Rate
Breast Cancer
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls…
- Trial name
- NCT01990352
- Testing
- Pegylated liposomal doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Carcinoma, Non-Small-Cell Lung
Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of endostatin combined with Docetaxel in advanced Non-Small-Cell Lung Carcinoma (NSCLC) patients failure to first-line or second-line chemotherapy.
- Trial name
- NCT01192230
- Testing
- Endostatins, Docetaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Epigenetic Biomarker for Osteosarcoma
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Conditions
- Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR, Progression-free Survival, PFS, Overall Survival, OS
- Trial name
- NCT03336554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Overall Response Rate
Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions
The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma
- Trial name
- NCT07090525
- Testing
- Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, cisplatin 40mg/m2 intracavity injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qingdao Central Hospital
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Renal Cancer, Birt-Hogg-Dube Syndrome
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Background: Research has shown that the drug everolimus can stop cancer cells from growing. It is approved for people with advanced kidney cancer.
- Trial name
- NCT02504892
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.
- Trial name
- NCT01893372
- Testing
- Eltrombopag, Hypomethylating Agent (HMA)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Mantle Cell Lymphoma
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
In this trial, patients with mantle cell lymphoma will be included, treatment with lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12 cycles, cycle length 28 days.
- Trial name
- PHILEMON (NCT02460276)
- Testing
- Lenalidomide, Ibrutinib, Rituximab
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 50 people
- Sponsor
- Lund University Hospital
Primary Central Nervous System Lymphoma
Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
This is a prospective multicenter single-arm phase II study, and the purpose of this study is to evaluate the efficiency of Orelabrutinib combined with PD-1 inhibitor regimen relapsed/refractory primary intraocular lymphoma.
- Trial name
- NCT04899427
- Testing
- orelabrutinib, Sintilimab, Tislelizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
GIST
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib.
- Trial name
- PAZOGIST (NCT01323400)
- Testing
- Pazopanib, Best supportive care
- Where
- 13 sites in France
- Volunteers
- 81 people
- Sponsor
- Centre Leon Berard
Relapsed/Refractory Multiple Myeloma
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT04896658
- Testing
- Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Refractory Chronic Lymphocytic Leukemia
Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL), an indolent disease of mature-looking B lymphocytes, is the most common leukemia in Israel and the Western world.
- Trial name
- NCT00892827
- Testing
- Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Wolfson Medical Center
Advanced Malignant Solid Tumors
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors.
- Trial name
- NCT05749627
- Testing
- Neoantigen peptide vaccine, Neoantigen-based DC immune preparation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Gastric Carcinoma
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT00970138
- Testing
- apatinib tablet
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Overall Response Rate
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
- Trial name
- NCT06277024
- Testing
- Combination of Cardonizumab with Lenvatinib and SOX regimen
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
NSCLC Stage IV
Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer
Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
- Trial name
- MWA in NSCLC (NCT04102982)
- Testing
- Camrelizumab, Camrelizumab plus microwave ablation
- Where
- 13 sites in China
- Volunteers
- 200 people
- Sponsor
- Shandong Provincial Hospital
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
This single arm study will evaluate the feasibility of treatment with 2 dose levels of Avastin in combination with concurrent thoracic radiation and chemotherapy in patients with locally advanced unresectable non-squamous…
- Trial name
- NCT00776698
- Testing
- bevacizumab [Avastin], cisplatin, etoposide
- Where
- 5 sites in Netherlands, United Kingdom
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving sorafenib together with docetaxel and cisplatin works in treating patients with metastatic or locally advanced gastric or gastroesophageal junction cancer that cannot be removed by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
- Trial name
- NCT00253370
- Testing
- BAY 43-9006, docetaxel, cisplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.
This single arm study will assess the efficacy and safety of Xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for…
- Trial name
- NCT00436241
- Testing
- Oxaliplatin, capecitabine [Xeloda]
- Where
- 13 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche